Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04328012 · ClinicalTrials.gov registry record · Phase 2
COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19
A Phase 2 study, sponsored by Bassett Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04328012 is a Phase 2 study that was terminated before completion, run by Bassett Healthcare. The registered enrollment target is 15 participants.
The verdict
NCT04328012, a Phase 2 study, was terminated before completion, sponsored by Bassett Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
In a randomized, double-blind, placebo-controlled, multi-center, Phase 2-like, investigator-directed trial, hospitalized adult patients with laboratory confirmed SARS-CoV-2 infection meeting inclusion and exclusion criteria, will be provided information on the trial, offered enrollment, and if informed consent provided, enrolled randomly in a 2:1 ratio to one of two groups: Group 1 standard care and losartan or Group 2 standard care and placebo. Patients will be followed for up to 60 days, with data collected to quantify the NCOSS over time (the primary objective), and for the trial's secondary objectives (see outcome measurements below).
Interventions
- DRUG Placebo
- DRUG Losartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2020-04-06 |
| Est. Completion | 2021-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04328012
The ClinicalTrials.gov registry entry for NCT04328012 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bassett Healthcare, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04328012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04328012 about?
NCT04328012 is a clinical study titled "COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19". In a randomized, double-blind, placebo-controlled, multi-center, Phase 2-like, investigator-directed trial, hospitalized adult patients with laboratory confirmed SARS-CoV-2 infection meeting inclusion and exclusion criteria, will be provided information on the trial, offered enrollment, and if infor...
What is the current status of trial NCT04328012?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2020-04-06. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT04328012?
The interventions under investigation include: Placebo (DRUG), Losartan (DRUG).
Who is sponsoring clinical trial NCT04328012?
This trial is sponsored by Bassett Healthcare, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.